Aurobindo Pharma Ltd (IN:AUROPHARMA)
:AUROPHARMA
Want to see IN:AUROPHARMA full AI Analyst Report?
Top Page
Aurobindo Pharma Ltd
(AUROPHARMA)
Select Model
Select Model
Rating:68Neutral
Price Target:
₹1,596.00
▲(32.19% Upside)
Action:Downgraded
Date:05/23/26
The score is driven by solid underlying financial health (steady growth, good profitability, and conservative leverage) but is held back by 2026 margin compression and only moderate returns. Technically, the uptrend is intact, yet overbought indicators (RSI/Stoch) add near-term risk. Valuation is moderate with a low dividend yield, offering limited downside cushion.
Positive Factors
Conservative leverage
A lower debt-to-equity and strengthening balance sheet provide durable financial flexibility: eases refinancing risk, supports investment in manufacturing capacity and regulatory compliance, and lets management pursue launches or absorb pricing shocks without forcing asset sales.
Negative Factors
Margin compression
A sustained drop in gross margins signals structural pricing pressure or cost escalation in core generics/API operations. Lower gross margins erode operating leverage, reduce funds available for reinvestment, and can materially compress future profit potential if persistent.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage
A lower debt-to-equity and strengthening balance sheet provide durable financial flexibility: eases refinancing risk, supports investment in manufacturing capacity and regulatory compliance, and lets management pursue launches or absorb pricing shocks without forcing asset sales.
Read all positive factors
Aurobindo Pharma Ltd (AUROPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹844.17B
Dividend Yield0.33%
Average Volume (3M)40.80K
Price to Earnings (P/E)21.6
Beta (1Y)0.72
Revenue Growth6.08%
EPS Growth0.77%
CountryIN
Employees26,015
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)58.93
Shares Outstanding580,801,640
10 Day Avg. Volume31,329
30 Day Avg. Volume40,801
Financial Highlights & Ratios
PEG Ratio24.40
Price to Book (P/B)2.00
Price to Sales (P/S)2.25
P/FCF Ratio26.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)76.17
Revenue Forecast (FY)₹384.38B
Aurobindo Pharma Ltd Business Overview & Revenue Model
Company Description
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-...
How the Company Makes Money
Aurobindo Pharma makes money mainly by selling pharmaceutical products across two core streams: (1) finished dosage formulations and (2) APIs/intermediates. Finished dosage formulations are sold to customers such as wholesalers, distributors, reta...
Aurobindo Pharma Ltd Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 325.14B | 336.53B | 317.24B | 290.02B | 248.55B | 234.55B |
| Gross Profit | 170.29B | 131.96B | 182.40B | 160.16B | 132.14B | 130.06B |
| EBITDA | 67.02B | 68.56B | 64.36B | 57.64B | 36.34B | 43.11B |
| Net Income | 34.22B | 35.05B | 34.86B | 31.73B | 19.27B | 26.48B |
Balance Sheet | ||||||
| Total Assets | 525.46B | 585.02B | 497.85B | 450.72B | 398.90B | 339.22B |
| Cash, Cash Equivalents and Short-Term Investments | 88.92B | 106.18B | 82.36B | 63.25B | 62.24B | 45.58B |
| Total Debt | 77.94B | 80.73B | 82.63B | 66.48B | 52.86B | 32.79B |
| Total Liabilities | 175.12B | 206.19B | 171.38B | 152.21B | 130.38B | 93.48B |
| Stockholders Equity | 350.41B | 378.91B | 326.53B | 298.43B | 268.40B | 245.76B |
Cash Flow | ||||||
| Free Cash Flow | 15.22B | 28.27B | 19.57B | -11.27B | -3.34B | 23.12B |
| Operating Cash Flow | 28.85B | 55.13B | 39.25B | 24.35B | 23.87B | 50.16B |
| Investing Cash Flow | -22.23B | -37.89B | -18.76B | -42.56B | -39.78B | -32.12B |
| Financing Cash Flow | -9.43B | -9.25B | 1.20B | 8.00B | 18.14B | -29.69B |
Aurobindo Pharma Ltd Technical Analysis
Neutral
1207.35
Price Trends
1386.36
Positive
1285.35
Positive
1205.10
Positive
Market Momentum
33.54
Positive
50.87
Neutral
43.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AUROPHARMA, the sentiment is Neutral. The current price of 1207.35 is below the 20-day moving average (MA) of 1468.47, below the 50-day MA of 1386.36, and above the 200-day MA of 1205.10, indicating a neutral trend. The MACD of 33.54 indicates Positive momentum. The RSI at 50.87 is Neutral, neither overbought nor oversold. The STOCH value of 43.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:AUROPHARMA.
Aurobindo Pharma Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹1.05T | 19.82 | ― | 0.57% | 23.12% | 62.27% | |
72 Outperform | ₹645.66B | 25.97 | ― | 0.80% | 11.73% | 10.02% | |
68 Neutral | ₹844.17B | 21.62 | ― | 0.33% | 6.08% | 0.77% | |
64 Neutral | ₹1.08T | 17.39 | ― | 1.19% | 16.81% | 11.38% | |
59 Neutral | ₹732.96B | 48.00 | ― | 0.15% | 22.67% | 147.76% | |
53 Neutral | ₹659.11B | 35.61 | ― | 0.24% | 25.44% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,463.75
277.25
23.37%
IN:ALKEM
Alkem Laboratories Ltd.
5,379.00
170.34
3.27%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,351.25
970.59
70.30%
IN:LAURUSLABS
Laurus Labs Ltd.
1,373.80
773.15
128.72%
IN:LUPIN
Lupin Limited
2,263.85
306.51
15.66%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,078.95
171.30
18.87%
Aurobindo Pharma Ltd Corporate Events
Aurobindo Pharma Replaces Secretarial Auditor After Health-Related Resignation
May 21, 2026
Aurobindo Pharma has announced the resignation of its secretarial auditor, MRR Associates, effective May 22, 2026, citing health issues of the firm’s sole proprietor. The change has been disclosed under SEBI’s Listing Regulations, wit...
Aurobindo Pharma appoints new secretarial auditor after resignation of incumbent firm
May 21, 2026
Aurobindo Pharma Ltd has announced a change in its secretarial audit arrangements, following the resignation of MRR Associates as secretarial auditor effective May 22, 2026, due to health issues of the firm’s sole proprietor. The Board, at ...
Aurobindo Pharma Reappoints EY as Internal Auditor for 2026–27
May 21, 2026
Aurobindo Pharma Ltd has reappointed Ernst Young LLP as its internal auditors for the period from June 2026 to May 2027, following approval by the board of directors at a meeting held on May 21, 2026. The move underscores the company’s emph...
Aurobindo Pharma’s Jedcherla Plant Cleared by US FDA With VAI Classification
May 6, 2026
Aurobindo Pharma has announced that its Unit-VII oral solid dosage manufacturing facility at the Special Economic Zone (Pharma) in Jedcherla, Telangana, has been classified as Voluntary Action Indicated by the U.S. Food and Drug Administration. Th...
Aurobindo Pharma Board Clears ₹800-Crore Share Buyback via Tender Offer
Apr 6, 2026
Aurobindo Pharma’s board has approved a share buyback of up to 5,423,728 fully paid equity shares, representing about 0.93% of its paid-up equity capital, at a price of ₹1,475 per share for a total consideration of up to ₹800 cro...
Aurobindo Pharma Transfers Domestic Branded Generics Business to Subsidiary
Apr 6, 2026
Aurobindo Pharma’s board has approved the transfer of its domestic branded generic pharmaceutical formulations business to its wholly owned subsidiary, Auropharm Limited, via a Business Transfer Agreement. The move aligns with the company...
Aurobindo Pharma Clears ₹800-Crore Share Buyback at ₹1,475 a Share
Apr 6, 2026
Aurobindo Pharma’s board has approved a share buyback of up to 5,423,728 fully paid equity shares, representing up to 0.93% of its paid-up equity capital, at a price of ₹1,475 per share for a total consideration of up to ₹800 cro...
Aurobindo Pharma Schedules Analyst and Investor Plant Visit to Vizag and Kakinada
Mar 11, 2026
Aurobindo Pharma Limited has notified stock exchanges that its officials will participate in an analyst and investor group plant visit on March 16, 2026. The in-person visit, scheduled from 9:00 a.m. to 5:00 p.m. IST, will take place at the compan...
Aurobindo Pharma Schedules Analyst and Investor Plant Visit to Vizag and Kakinada
Mar 11, 2026
Aurobindo Pharma has notified stock exchanges that its officials will participate in an in-person analyst and investor group plant visit to its facilities in Vizag and Kakinada on March 17, 2026, scheduled from 9:00 a.m. to 5:00 p.m. Indian Standa...
Aurobindo Pharma to Join Goldman Sachs India Pharma Corporate Days Investor Meet
Mar 2, 2026
Aurobindo Pharma Limited has notified stock exchanges that its officials will participate in Goldman Sachs India Pharma Corporate Days, an investor conference scheduled as a virtual meeting on March 6, 2026. The company emphasized that no unpublis...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.